Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Pathak, S. Goldberg, M. Canavan, J. Herrin, J. Hoag, Michelle Salazar, M. Papageorge, T. Ermer, D. Boffa (2020)
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.JAMA oncology
S. Bains, T. Eguchi, A. Warth, Y. Yeh, J. Nitadori, K. Woo, T. Chou, H. Dienemann, T. Muley, J. Nakajima, A. Shinozaki-Ushiku, Yu-Chung Wu, Shaohua Lu, K. Kadota, David Jones, W. Travis, K. Tan, P. Adusumilli (2019)
Procedure‐Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort AnalysisJournal of Thoracic Oncology, 14
S. Burdett, J. Pignon, J. Tierney, H. Tribodet, L. Stewart, C. Péchoux, A. Aupérin, T. Chevalier, R. Stephens, R. Arriagada, J. Higgins, David Johnson, J. Meerbeeck, M. Parmar, R. Souhami, B. Bergman, J. Douillard, A. Dunant, C. Endo, D. Girling, H. Kato, S. Keller, H. Kimura, A. Knuuttila, K. Kodama, R. Komaki, M. Kris, T. Lad, T. Mineo, S. Piantadosi, R. Rosell, G. Scagliotti, L. Seymour, F. Shepherd, R. Sylvester, H. Tada, F. Tanaka, V. Torri, D. Waller, Ying-ying Liang (2015)
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.The Cochrane database of systematic reviews, 3
M. Tsao, S. Marguet, G. Teuff, S. Lantuejoul, F. Shepherd, L. Seymour, R. Kratzke, S. Graziano, H. Popper, R. Rosell, J. Douillard, Thierry Le-Chevalier, J. Pignon, J. Soria, E. Brambilla (2015)
Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 30
J. Dai, Ming Liu, Yang Yang, Qiuyuan Li, Nan Song, G. Rocco, A. Sihoe, D. González-Rivas, H. Suen, Wen-xin He, L. Duan, Jiang Fan, Deping Zhao, Hai-feng Wang, Yuming Zhu, Chang Chen, R. Diasio, G. Jiang, Ping Yang, Peng Zhang (2019)
Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 14 7
Letters submitted work. Dr Bal reported receiving grants from Amyloidosis Foundation significant difference between the study by Premkumar et al outside the submitted work. Dr Costa reported receiving grants and personal and ours is the length of follow-up. Whereas the former used fees from Janssen during the submitted work and grants and personal fees from the original MAIA publication with a median follow-up of 28 Amgen and personal fees from Bristol Myers Squibb and Sanofi outside the months, we used the more recent update of this trial submitted work. (NCT02252172) with a median follow-up of 36 months. It 1. Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic appears that the progression-free survival benefit in the review and meta-analysis. JAMA Oncol. 2020;6(11):1-8. doi:10.1001/jamaoncol. daratumumab arm deepened with extended follow-up, leading 2020.4338 to lower hazard ratio and reaching our preestablished threshold 2. Mohyuddin GR, Sigle M, Chandrasekar VT, et al. Impact of anti-CD38 therapy of statistical significance. in multiple myeloma with high-risk cytogenetics: systematic review and In their comments, Mohyuddin et al question the benefit meta-analysis. Leuk Lymphoma. 2020;61(10):2519-2522. doi:10.1080/ 10428194.2020.1772475 of daratumumab in
JAMA Oncology – American Medical Association
Published: Apr 25, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.